COVID-19 ve Diyabet - Sıklık ve Prognoz: Tek Merkez Deneyimi

Year 2021, , 180 - 185, 29.08.2021

Kadem Arslan , Süleyman Baş

https://doi.org/10.25048/tudod.904249

Cited By: 1

Abstract

Amaç: COVID-19 hastalarında diyabet prevalansını ve diyabetin COVID-19 hastalığının seyrine etkisini araştırmayı amaçladık.
Gereç ve Yöntemler: Çalışmaya 01/06/2020-30/10/2020 tarihleri arasında İstanbul Sancaktepe Şehit Prof.Dr. İlhan Varank Eğitim ve Araştırma Hastanesi'nde COVID-19 tanısı alan hastalar dahil edildi.Hastane bilgi yönetim sisteminden hastaların tıbbi kayıtları araştırıldı.Hastaların tıbbi geçmişlerini,PCR test sonuçlarını,kan testi sonuçlarını,bilgisayarlı tomografi raporlarını,hastaneye yatış durumlarını ve tedavi sonuçlarını incelendi.
Bulgular: Çalışmaya 1145 kadın ve 1269 erkek olmak üzere toplam 2414 hasta dahil edildi.Tüm gruptaki diyabet prevalansı % 18.6 saptandı. Diyabetiklerde; hastaneye yatış oranı ve yoğun bakıma yatış oranı diyabetik olmayanlara göre anlamlı olarak daha yüksekti. Diyabetik grupta, hastanede ve yoğun bakımda yatış süreleri anlamlı olarak daha yüksekti. Diyabetiklerde,tomografide pnömoni varlığı oranı anlamlı olarak daha yüksektiDiyabetik hastalarda ölüm oranı daha yüksekti.
Sonuç: Diyabet, COVID-19 hastalarında daha kötü klinik sonuçlara yol açabilir. COVID-19, diyabetik hastalarda daha ölümcül olabilir.

Keywords

COVID-19, SARS COV2, Diyabet, Prognoz

COVID-19 and Diabetes - Prevalence and Prognosis: A Single-Center Experience

Abstract

Aim: We aimed to investigate the prevalence of diabetes in COVID-19 patients and the effect of diabetes on the course of COVID-19 disease.
Material and Methods: Patients diagnosed with COVID-19 disease in Istanbul Sancaktepe Martyr Prof. Dr. Ilhan Varank Training and Research Hospital between 01/06/2020 and 30/10/2020 were included in the study. Medical records of patients were analyzed from the hospital information management system. We examined medical history, PCR test results, blood test results, computerised tomography
reports, hospitalization and treatment results.
Results: 2414 patients, 1145 females and 1269 males were included in the study. The diabetes prevalence in the whole group was 18.6%. The rate of hospitalization and the rate of admission to intensive care unit was significantly higher in diabetics than non-diabetics. In the diabetic group; total length of stay in hospital and intensive care unit was significiantly higher. The rate of presence of pneumonia on
tomography was significantly higher in diabetics. The mortality rate was significiantly higher in diabetics than non-diabetics.
Conclusion: We found the prevalence of diabetes in COVID-19 patients to be 18.6%. The rate of presence of pneumonia on thorax CT, the rate of hospitalization and the rate of admission to the intensive care unit were found to be significantly higher in diabetics. The mortality rate was found to be higher in COVID-19 patients with diabetes. Diabetes mellitus may lead to worse clinical outcomes in
COVID-19 patients. COVID-19 may be more mortal in diabetic patients.

Keywords

COVID-19, Diabetes, Coronavirus, SARS-CoV-2, Prognosis

References

• Reference1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
• Reference2. Poutanen SM. Etiologic agents of infectious diseases. In: Long SS, editor. Principles and practice of paediatric infectious diseases. 4th ed. 2012. p. 1547–712.
• Reference3. Zhang, H., Penninger, J. M., Li, Y., Zhong, N. & Slutsky, A. S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 46, 586–590 (2020).
• Reference4. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
• Reference5. Knapp S. Diabetes and infection:is there a link?- A mini review Gerontology, 2013;59:99-104.
• Reference6. Reza F, Nader B , Esfandiar H, et al. Serum levels of IL-32 in patients with type 2 diabetes mellitus and its relationship with TNF-α and IL-6.Cytokine 125 (2020) 154832.
• Reference7. Travis B.，Paul P., Jun Y, et al. Diabetes Exacerbates Infection via Hyperinflammation by Signaling through TLR4 and RAGE. mBio, 2017 8:e00818-17.
• Reference8. Allison L.T., Alan W., Sudhakar A., et al. Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection. mBio, 2015 , 3:e00638-15.
• Reference9. Geerlings S.E., Hoepelman A.I. Immune dysfunction in patients with diabetes mellitus (DM) FEMS Immunol Med Microbiol, 1999 Dec;26(3-4):259-65.
• Reference10. Hinissan P. Kohio, Amy L. Adamson Glycolytic control of vacuolar-type ATPase activity: a mechanism to regulate influenza viral infection Virology, (2013).444, 1-2. Reference11. Satman İ, Alagöl F, Ömer B, Kalaca S, Tütüncü Y, Çolak N. Türkiye Diyabet, Hipertansiyon, Obezite ve Endokrinolojik Hastalıklar Prevalans Çalışması-II. (TURDEP II) 2011.
• Reference12. SingH A.K., Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 14 (2020) 303e310.
• Reference13. Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. Int J Obes (Lond). 2013;37:333–40.
• Reference14. Dunn E.J., Grant P.J. Type 2 diabetes: an atherothrombotic syndrome Curr Mol Med, 2005;5:323–332.